Ken Griffin 4 D Molecular Therapeutics, Inc. Transaction History

Citadel Advisors LLC

$509 Billion
Q1 2025

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in 4 D Molecular Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 25,800 shares of FDMT stock, worth $84,366. This represents 0.0% of its overall portfolio holdings.

Number of Shares

25,800

Previous 46,100 44.03%

Holding current value

$84,366

Previous $256,000 67.58%

% of portfolio

0.0%

Previous 0.0%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$3.23 - $6.6 $884,635 - $1.81 Million	-273,881 Reduced 45.26%	331,211 $1.07 Million
Q4 2024 Feb 14, 2025	BUY	$5.3 - $10.41 $2.53 Million - $4.97 Million	477,444 Added 374.03%	605,092 $3.37 Million
Q3 2024 Nov 14, 2024	BUY	$10.81 - $27.22 $588,604 - $1.48 Million	54,450 Added 74.39%	127,648 $1.38 Million
Q2 2024 Aug 14, 2024	SELL	$20.93 - $30.01 $314,598 - $451,080	-15,031 Reduced 17.04%	73,198 $1.54 Million
Q1 2024 May 15, 2024	BUY	$17.03 - $35.87 $1.19 Million - $2.5 Million	69,671 Added 375.42%	88,229 $2.81 Million
Q4 2023 Feb 14, 2024	SELL	$9.76 - $21.25 $1.22 Million - $2.65 Million	-124,662 Reduced 87.04%	18,558 $375,000
Q3 2023 Nov 14, 2023	BUY	$12.64 - $19.76 $1.57 Million - $2.46 Million	124,335 Added 658.38%	143,220 $1.82 Million
Q2 2023 Aug 14, 2023	BUY	$15.16 - $23.26 $212,437 - $325,942	14,013 Added 287.62%	18,885 $341,000
Q1 2023 May 15, 2023	BUY	$15.45 - $23.19 $75,272 - $112,981	4,872 New	4,872 $83,000
Q3 2022 Nov 14, 2022	SELL	$6.96 - $11.48 $713,281 - $1.18 Million	-102,483 Reduced 45.56%	122,459 $984,000
Q2 2022 Aug 15, 2022	BUY	$5.68 - $15.99 $1 Million - $2.82 Million	176,409 Added 363.48%	224,942 $1.57 Million
Q1 2022 May 16, 2022	BUY	$13.16 - $22.64 $219,192 - $377,091	16,656 Added 52.25%	48,533 $733,000
Q4 2021 Feb 14, 2022	BUY	$19.56 - $32.94 $352,881 - $594,270	18,041 Added 130.39%	31,877 $699,000
Q3 2021 Nov 15, 2021	SELL	$22.73 - $36.04 $306,309 - $485,675	-13,476 Reduced 49.34%	13,836 $373,000
Q2 2021 Aug 16, 2021	BUY	$22.2 - $42.29 $170,851 - $325,463	7,696 Added 39.23%	27,312 $657,000
Q1 2021 May 17, 2021	SELL	$35.94 - $52.67 $1.18 Million - $1.73 Million	-32,847 Reduced 62.61%	19,616 $851,000
Q4 2020 Feb 16, 2021	BUY	$38.43 - $47.36 $2.02 Million - $2.48 Million	52,463 New	52,463 $2.18 Million

Others Institutions Holding FDMT

# of Institutions

130

Shares Held

46.8M

Call Options Held

25.8K

Put Options Held

33.4K

View Full List

About 4D Molecular Therapeutics, Inc.

Ticker FDMT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,382,400
Market Cap $106M
Description
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical tr...

More about FDMT

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account